ClinicalTrials.gg
TerminatedNCT00686881Updated Apr 6, 2017Results posted

Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)

A Phase 3 interventional study of Peginterferon alfa-2b (PegIFN-2b) and Comparator: Stronger neo minophagen C (SNMC) in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-04-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
This study was terminated due to low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
10th of 39
261 · median 99
Started
2006
with 5 others
Phase 3
22 of 40
none open now
Registered
21st of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 10th largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2006, is one of 22 in phase 3, and was the 21st registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

The objective of this study is to compare the efficacy of peginterferon alfa-2b (PegIFN-2b) monotherapy administered at a dose of 0.5 ug/kg vs stronger neo minophagen C (SNMC) in participants with chronic hepatitis C (CHC) and liver fibrosis (Metavir fibrosis score of F2 and F3) who were previously treated with interferon. The trial will evaluate the effect of treatment on the progression of liver fibrosis, liver inflammation, and liver function. Treatment will be administered for up to 156 weeks with a 4-week follow-up.

03

Conditions studied

  • Hepatitis C, Chronic

Keywords

  • hepatitis C
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with chronic previously treated with interferon
  • At least 20 years of age
  • Liver fibrosis score rated as F2 or F3 based on the result of liver at screening
  • Female patients willing to use
  • Body weight from 35.0 kg to 110.0 kg (inclusive)
  • Positive for hepatitis C virus ribonucleic acid (HCV-RNA) by qualitative assay
  • Patients who meet the following laboratory criteria:

    • Serum (ALT) level: >60 IU/L
    • : >=1,200/mm\^3
    • count: >=100,000/mm\^3
    • Serum potassium level: >=3.5 mEq/L

Exclusion criteria

Exclusion Criteria:

  • Patients who received interferon therapy within 90 days of Screening
  • Patients who have received antiviral agents or antitumor agents, or immunomodulator therapy (including chronic and radiotherapy) within 90 days of Screening (excluding local administration and topical use)
  • Patients who have received other drugs within 90 days of Screening
  • surface antigen (HBs)positive
  • Antinuclear antibody titer of 1:320 or higher
  • Creatinine level exceeding the upper limit of the reference range measured at screening test 2;
  • Fasting blood glucose level of >=126 mg/dL
  • Patients on insulin therapy regardless of the fasting blood glucose level
  • Patients who have a concurrent or past history of any of the following conditions: liver cirrhosis, liver failure, or liver carcinoma; hepatic encephalopathy, esophageal varices requiring treatment, or ascites; suicidal attempt or ideation; epileptic seizures requiring drug therapy; angina pectoris, heart failure, myocardial infarction or fatal arrhythmia; disease (Hashimoto's disease [chronic thyroiditis], Crohn's disease, ulcerative colitis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, etc.); malignant tumors (it is permitted to register patients with at least 5 years after cure).
  • Patients who concurrently have any of the following conditions: liver disease such as autoimmune hepatitis, alcoholic liver injury, and drug-induced hepatitis; hemophilia; depression or schizophrenia which requires treatment; hypertension which cannot be controlled by drug therapy or arrhythmia which requires treatment, chronic pulmonary disease; abnormal thyroid function that cannot be controlled by drug therapy; organ transplants (other than corneal, hair transplant, etc.); aldosteronism, myopathy, or hypokalemia.
  • Patients with a history of to interferon preparations or biological products such as vaccines
  • Patients with a history of hypersensitivity to monoammonium glycyrrhizinate, glycine, or L-cysteine monohydrochloride;
  • Women who are pregnant or lactating, and women in whom pregnancy cannot be ruled out based on the result of serum human chorionic gonadotropin (HCG) measurement at Screening
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
261 participants (actual)

Study arms

  • Experimental
    PegIFN-2b

    Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.

    Biological: Peginterferon alfa-2b (PegIFN-2b)

  • Active comparator
    SNMC

    Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.

    Drug: Comparator: Stronger neo minophagen C (SNMC)

Interventions

  • PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks

    Also known as: SCH 054031, Pegylated interferon alfa-2b

  • DrugComparator: Stronger neo minophagen C (SNMC)

    SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .

06

What researchers measure

Primary outcomes

  1. Number of Participants With Change in Metavir Fibrosis Score

    Metavir fibrosis score is a 5-point scale based on the amount of fibrosis in the liver, ranging from F0 (best, no fibrosis) to F4 (worst, cirrhosis).

    Time frame: Baseline and discontinuation of treatment (up to 156 weeks)

Secondary outcomes

  1. Number of Participants With Alanine Aminotransferase (ALT) Normalization of >16 Weeks Duration

    The ALT was judged to have been normalized when the ALT level was 35 IU/L or below.

    Time frame: Week 24

  2. Number of Participants With Change in Metavir Inflammation Score

    Metavir inflammation score is a 4-point scale based on the severity of inflammation in the liver, ranging from A0 (best, no activity) to A3 (worst, severe activity).

    Time frame: Baseline and Week 48

07

Results

Posted Mar 6, 2012
Limitations and caveats
This study was prematurely discontinued because of low enrollment.

Participant flow

Participant flow — Overall Study
MilestonePegIFN-2bSNMC
Started127134
Completed4553
Not completed8281
Withdrew: Withdrawal by subject1118
Withdrew: Lost to follow-up01
Withdrew: Treatment-related adverse event109
Withdrew: Met discontinuation criteria50
Withdrew: Onset of malignant tumor1111
Withdrew: Lack of efficacy43
Withdrew: Physician decision10
Withdrew: Circumstances of site11
Withdrew: Did not meet protocol eligibility10
Withdrew: Irregular visits10
Withdrew: Study discontinuation3532
Withdrew: Never received study drug26

Outcome measures

PrimaryNumber of Participants With Change in Metavir Fibrosis Score

Metavir fibrosis score is a 5-point scale based on the amount of fibrosis in the liver, ranging from F0 (best, no fibrosis) to F4 (worst, cirrhosis).

Time frame:
Baseline and discontinuation of treatment (up to 156 weeks)
Reported as:
Number · Participants
Number of Participants With Change in Metavir Fibrosis Score
ParticipantsPegIFN-2bSNMC
Participants with ≥1grade lower score (improved)1311
Participants with no change in score7979
Participants with ≥1 grade higher score (worsened)3136
SecondaryNumber of Participants With Alanine Aminotransferase (ALT) Normalization of >16 Weeks Duration

The ALT was judged to have been normalized when the ALT level was 35 IU/L or below.

Time frame:
Week 24
Reported as:
Number · Participants
Number of Participants With Alanine Aminotransferase (ALT) Normalization of >16 Weeks Duration
ParticipantsPegIFN-2bSNMC
Number of Participants With Alanine Aminotransferase (ALT) Normalization of >16 Weeks Duration92
SecondaryNumber of Participants With Change in Metavir Inflammation Score

Metavir inflammation score is a 4-point scale based on the severity of inflammation in the liver, ranging from A0 (best, no activity) to A3 (worst, severe activity).

Time frame:
Baseline and Week 48
Reported as:
Number · Participants
Number of Participants With Change in Metavir Inflammation Score
ParticipantsPegIFN-2bSNMC
Participants with ≥1grade lower score (improved)4823
Participants with no change in score5561
Participants with ≥1grade higher score (worsened)1942

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PegIFN-2b—32/125 (25.6%)125/125 (100%)
SNMC—23/127 (18.1%)123/127 (96.9%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventPegIFN-2bSNMC
HEPATIC NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)8/12510/127
DEAFNESS NEUROSENSORYEar and labyrinth disorders1/1250/127
MENIERE'S DISEASEEar and labyrinth disorders1/1250/127
DUODENAL ULCERGastrointestinal disorders1/1250/127
GINGIVAL BLEEDINGGastrointestinal disorders1/1250/127
PANCREATITISGastrointestinal disorders1/1250/127
PANCREATITIS ACUTEGastrointestinal disorders1/1250/127
VARICES OESOPHAGEALGastrointestinal disorders1/1250/127
PYREXIAGeneral disorders1/1250/127
APPENDICITISInfections and infestations1/1250/127
Most frequent other events
Showing 10 of 82
Most frequent other events
EventPegIFN-2bSNMC
MALAISEGeneral disorders97/12551/127
PYREXIAGeneral disorders87/12525/127
HEADACHENervous system disorders82/12542/127
LYMPHOCYTE COUNT DECREASEDInvestigations80/12545/127
NASOPHARYNGITISInfections and infestations77/12581/127
PLATELET COUNT DECREASEDInvestigations74/12519/127
ARTHRALGIAMusculoskeletal and connective tissue disorders72/12531/127
WHITE BLOOD CELL COUNT DECREASEDInvestigations68/1259/127
MYALGIAMusculoskeletal and connective tissue disorders68/12524/127
HYALURONIC ACID INCREASEDInvestigations62/12546/127

Baseline characteristics

Age, Continuous
Age, Continuous(years)PegIFN-2bSNMCTotal
Mean59.8 ± 9.560.7 ± 8.960.3 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)PegIFN-2bSNMCTotal
Female6065125
Male6562127
Region of Enrollment
Region of Enrollment(participants)PegIFN-2bSNMCTotal
Japan125127252
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 30, 2008
Start
Dec 2006
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results first posted
Mar 6, 2012
Last update
Apr 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00686881
Responsible party
Sponsor
First posted
May 30, 2008
Start date
Dec 2006
Primary completion
Feb 2011
Completion
Feb 2011
Results posted
Mar 6, 2012
Last update
Apr 6, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion